Evaluation of the causal effects of blood metabolites on irritable bowel syndrome: Mendelian randomization

BMC Gastroenterology

Table 1 Three MR models tested for heterogeneity and horizontal pleiotropy and assessed the causal associations between seven recognized metabolites and the probability of IBS

Metabolite	Methods	SNP (n)	OR (95%CI)	P	Heterogeneity		Pleiotropy Intercept		Power
Metabolite	Methods	SNP (n)	OR (95%CI)	P	Q	P	P		Power
1-palmitoylglycerophosphocholine	IVW	34	0.58 (0.43–0.78)	0.0003	37.82	0.26	0.004	0.35	0.99
	WM	34	0.53 (0.35–0.80)	0.002
	MR Egge	34	0.39 (0.16–0.93)	0.043
stearate (18:0)	IVW	43	0.74 (0.59–0.92)	0.007	38.39	0.63	0.003	0.35	0.88
	WM	43	0.75 (0.55–1.02)	0.069
	MR Egger	43	0.57 (0.32–1.02)	0.063
1-palmitoylglycerophosphoinositol	IVW	11	0.84 (0.71–0.99)	0.034	6.25	0.79	0.003	0.45	0.97
	WM	11	0.74 (0.59–0.92)	0.008
	MR Egger	11	0.75 (0.53–1.05)	0.131
1-palmitoylglycerol	IVW	14	1.49 (1.07–2.07)	0.019	21.27	0.067	0.002	0.81	0.84
	WM	14	1.30 (0.89–1.91)	0.170
	MR Egge	14	1.72 (0.54–5.48)	0.380
arginine	IVW	21	1.36 (1.07–1.74)	0.012	20.21	0.45	−0.004	0.46	0.86
	WM	21	1.39 (0.99–1.95)	0.057
	MR Egger	21	1.81 (0.83–3.95)	0.152
methionine	IVW	22	1.66 (1.02–2.71)	0.04	21	0.52	0.005	0.51	1.00
	WM	22	1.62 (0.80–3.26)	0.057
	MR Egger	22	0.93 (0.16–5.45)	0.152
valine	IVW	6	053 (0.29–0.95)	0.03	5	0.86	−0.001	0.77	0.82
	WM	6	0.63 (0.30–1.32)	0.22
	MR Egger	6	0.58 (0.26–1.29)	0.25

OR odds ratio, SNP single-nucleotide polymorphisms, IVW inverse variance weighting, MR Mendelian randomization, WM weighted median

ISSN: 1471-230X